{"id":"https://openalex.org/W20200451","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.9073","title":"Model-based evaluation of ipilimumab dosage regimen in patients with advanced melanoma","display_name":"Model-based evaluation of ipilimumab dosage regimen in patients with advanced melanoma","alternate_titles":[],"publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W20200451","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.9073","mag":"20200451"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.9073","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.9073","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.9073","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W20200451"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"D. Dai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Dai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031645104","display_name":"Chunli Wu","orcid":"https://orcid.org/0000-0001-5658-6969","observed_orcids":["https://orcid.org/0000-0001-5658-6969"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110111346","display_name":"Susan M. Parker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. M. Parker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019908292","display_name":"Maria Jure\u2010Kunkel","orcid":"https://orcid.org/0000-0002-3751-1934","observed_orcids":["https://orcid.org/0000-0002-3751-1934"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. N. Jure-Kunkel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111986717","display_name":"Markus Pfister","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Pfister","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"D. Berman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Berman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5103164539","display_name":"Amit Roy","orcid":"https://orcid.org/0000-0003-2140-1455","observed_orcids":["https://orcid.org/0000-0003-2140-1455"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Roy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"9073","last_page":"9073"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.9430000185966492},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.9269999861717224},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9110000133514404},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.734000027179718},{"id":"https://openalex.org/keywords/trough-concentration","display_name":"trough concentration","score":0.5740000009536743},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7260000109672546},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.6039999723434448},{"id":"https://openalex.org/keywords/nonlinear-mixed-effects-models","display_name":"nonlinear mixed-effects models","score":0.6909999847412109},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.4729999899864197},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.621999979019165},{"id":"https://openalex.org/keywords/budesonide","display_name":"budesonide","score":0.7490000128746033},{"id":"https://openalex.org/keywords/il-2-therapy","display_name":"IL-2 therapy","score":0.8700000047683716},{"id":"https://openalex.org/keywords/drug-efficacy-and-safety","display_name":"drug safety and efficacy","score":0.41200000047683716}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.899568498134613},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8573058247566223},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6296752095222473},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.54730224609375},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.529646635055542},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5271677374839783},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.48617714643478394},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4834635853767395},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42057543992996216},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3269810378551483},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3172895312309265},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.245999276638031},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.11136722564697266}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.9073","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.9073","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.9073","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1950972410","https://openalex.org/W2112196468","https://openalex.org/W2599897482","https://openalex.org/W2951343526","https://openalex.org/W2260073192","https://openalex.org/W2984684785","https://openalex.org/W3094017079","https://openalex.org/W2095826876","https://openalex.org/W2132197524","https://openalex.org/W2589804830"],"abstract_inverted_index":{"9073":[0],"Background:":[1],"Ipilimumab":[2,115,175,203],"is":[3],"a":[4,120,161],"fully":[5],"human":[6],"monoclonal":[7],"antibody":[8],"that":[9,108],"enhances":[10],"antitumor":[11],"immune":[12],"response":[13,276],"by":[14,36,119,166,218],"selectively":[15],"binding":[16,157],"to":[17,44,60,128,158,179,215],"cytotoxic":[18],"T":[19],"lymphocyte":[20],"antigen-4":[21],"(CTLA-4)":[22],"expressed":[23],"on":[24,139],"activated":[25],"T-cells,":[26],"thereby":[27],"preventing":[28],"the":[29,37,46,62,143,185,244,256,302],"inhibitory":[30],"modulation":[31],"of":[32,50,70,132,147,155,194,241,259],"T-cell":[33],"activation":[34],"promoted":[35],"CTLA-4/B7":[38],"interaction.":[39],"Our":[40],"objectives":[41],"were":[42,82,103,136,262,270],"(i)":[43],"characterize":[45],"extent":[47],"and":[48,58,91,96,112,165,172,182,247,265,277,282,304],"variability":[49],"ipilimumab":[51,105],"exposure":[52],"in":[53,67,152,160,184,208,243,297],"patients":[54,69,141,242,300],"with":[55,84,199,206,251],"advanced":[56,298],"melanoma,":[57],"(ii)":[59],"evaluate":[61],"proposed":[63,290],"induction":[64,106,294],"dose":[65,186],"regimen":[66,296],"these":[68],"four":[71],"10":[72,113,248,291],"mg/kg":[73,249,292,306],"doses":[74,107],"every":[75],"3":[76,88,246,305],"weeks":[77],"(Q3W).":[78],"Methods:":[79],"The":[80,189,239],"analyses":[81],"performed":[83],"data":[85,98],"collected":[86],"from":[87,99],"monotherapy":[89],"studies":[90],"included":[92],"pharmacokinetic":[93],"(PK),":[94],"efficacy,":[95],"safety":[97],"419":[100],"patients,":[101],"who":[102],"given":[104],"ranged":[109],"between":[110],"0.3":[111,303],"mg/kg.":[114],"PK":[116,176],"was":[117,126,177,196],"characterized":[118,271],"compartmental":[121],"nonlinear":[122],"mixed-effects":[123],"model,":[124],"which":[125],"applied":[127],"estimate":[129],"individual":[130],"measures":[131],"exposure.":[133],"Dosage":[134],"regimens":[135],"evaluated":[137],"based":[138],"%":[140,240],"attaining":[142],"target":[144,257],"trough":[145,252],"concentration":[146],"20":[148,260],"\u03bcg/mL":[149,261],"(which":[150],"resulted":[151],"maximal":[153],"blockade":[154],"CTLA-4":[156],"B7\u20131":[159],"cell-based":[162],"competition":[163],"assay),":[164],"exposure-response":[167],"(E-R)":[168],"relationships":[169,269],"for":[170,272],"efficacy":[171],"safety.":[173],"Results:":[174],"found":[178],"be":[180,216,284],"linear":[181],"time-invariant":[183],"range":[187],"tested.":[188],"model":[190],"estimated":[191],"geometric":[192],"mean":[193],"clearance":[195,204],"14.9":[197],"mL/h":[198],"34%":[200],"between-subject":[201],"variability.":[202],"increases":[205],"increase":[207],"body":[209],"weight,":[210],"but":[211],"does":[212],"not":[213],"appear":[214],"affected":[217],"concomitant":[219],"budesonide,":[220],"prior":[221,224],"IL-2":[222],"therapy,":[223,226],"systemic":[225],"sex,":[227],"age,":[228],"hepatic":[229],"function":[230,237],"(alkaline":[231],"phosphatase,":[232],"AST,":[233],"ALT)":[234],"or":[235,311,314],"renal":[236],"(GFR).":[238],"0.3,":[245],"groups":[250],"concentrations":[253],"higher":[254],"than":[255],"value":[258],"0%,":[263],"\u223c30%":[264],"\u223c95%,":[266],"respectively.":[267],"Exposure-response":[268],"best":[273],"overall":[274],"tumor":[275],"Gr3+":[278],"immune-related":[279],"adverse":[280],"events,":[281],"will":[283],"presented.":[285],"Conclusions:":[286],"Model-based":[287],"assessment":[288],"supports":[289],"Q3W":[293],"dosage":[295],"melanoma":[299],"over":[301],"regimens.":[307],"Author":[308],"Disclosure":[309],"Employment":[310],"Leadership":[312],"Consultant":[313],"Advisory":[315],"Role":[316],"Stock":[317],"Ownership":[318],"Honoraria":[319],"Research":[320],"Expert":[321],"Testimony":[322],"Other":[323],"Remuneration":[324],"Bristol-Myers":[325,327],"Squibb":[326,328]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W20200451","counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}
